A PHASE 2, OPEN-LABEL, RANDOMIZED STUDY OF LIVMONIPLIMAB IN COMBINATION WITH BUDIGALIMAB VERSUS CHEMOTHERAPY IN SUBJECTS WITH METASTATIC UROTHELIAL CARCINOMA

Registry ID

M25-204

Source registry

HEALTH_CANADA

Status

Ongoing

Phase

PHASE2

Study type

INTERVENTIONAL

Sponsor

ABBVIE CORPORATION

Start date

2025-06-23

Last update

2024-11-06

Conditions

• CARCINOMA

Related clinical trials

• A RANDOMIZED PHASE II, DOUBLE-BLIND, MULTICENTER STUDY OF AUTOGENE CEVUMERAN PLUS NIVOLUMAB VERSUS PLACEBO PLUS NIVOLUMAB AS ADJUVANT THERAPY IN PATIENTS WITH HIGH-RISK MUSCLE-INVASIVE UROTHELIAL CARCINOMA
• A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO- AND ACTIVE-COMPARATOR-CONTROLLED CLINICAL STUDY OF ADJUVANT V940 (MRNA-4157) PLUS PEMBROLIZUMAB VERSUS ADJUVANT PLACEBO PLUS PEMBROLIZUMAB IN PARTICIPANTS WITH HIGH-RISK MUSCLE-INVASIVE UROTHELIAL CARCINOMA POST-RADICAL RESECTION
• A PHASE II STUDY OF FLUORINE-148 (18F)-LABELED PSMA-1007 IN PATIENTS WITH KNOWN OR SUSPECTED METASTATIC PROSTATIC CARCINOMA
• "A PHASE 3 RANDOMIZED, DOUBLE BLIND STUDY OF PEMBROLIZUMAB PLUS GEMCITABINE/CISPLATIN VERSUS PLACEBO PLUS GEMCITABINE/CISPLATIN AS FIRST-LINE THERAPY IN PARTICIPANTS WITH ADVANCED AND/OR UNRESECTABLE BILIARY TRACT CARCINOMA.
• A PHASE 1 A/2A COHORT DOSE ESCALATION TRIAL TO DETERMINE THE SAFETY, TOLERANCE, MAXIMUM TOLERATED DOSE AND PRELIMINARY ANTINEOPASTIC ACTIVITY OF AVID100, AN ANTI-HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR MONOCLONAL ANTIBODY LINKED TO THE MAYTANSINOID OM 1
• A PHASE 1 STUDY OF ASP8374, AN IMMUNE CHECKPOINT INHIBITOR, AS A SINGLE AGENT IN SUBJECTS WITH LOCALLY ADVANCED OR METASTATIC CARCINOMA

View on source registry